Orchestra Biomed Holdings Stock Analysis
| OBIO Stock | 5.57 0.20 3.47% |
Orchestra BioMed Holdings is undervalued with Real Value of 9.04 and Target Price of 20.33. The main objective of Orchestra BioMed stock analysis is to determine its intrinsic value, which is an estimate of what Orchestra BioMed Holdings is worth, separate from its market price. There are two main types of Orchestra BioMed's stock analysis: fundamental analysis and technical analysis.
The Orchestra BioMed stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Orchestra BioMed is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Orchestra Stock trading window is adjusted to America/New York timezone.
Orchestra |
Orchestra Stock Analysis Notes
About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Orchestra BioMed was now reported as 1.22. The company recorded a loss per share of 1.6. Orchestra BioMed Holdings had not issued any dividends in recent years. To find out more about Orchestra BioMed Holdings contact the company at 212 862 5797 or learn more at https://orchestrabiomed.com.Orchestra BioMed Holdings Investment Alerts
| Orchestra BioMed generated a negative expected return over the last 90 days | |
| Orchestra BioMed has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.76 M. Net Loss for the year was (49.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Orchestra BioMed generates negative cash flow from operations | |
| About 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Pivots Trading Plans and Risk Controls - Stock Traders Daily |
Orchestra BioMed Holdings Upcoming and Recent Events
Earnings reports are used by Orchestra BioMed to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Orchestra Largest EPS Surprises
Earnings surprises can significantly impact Orchestra BioMed's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-13 | 2024-06-30 | -0.4 | -0.45 | -0.05 | 12 | ||
2023-08-10 | 2023-06-30 | -0.41 | -0.35 | 0.06 | 14 | ||
2023-05-12 | 2023-03-31 | -0.28 | -0.4 | -0.12 | 42 |
Orchestra BioMed Environmental, Social, and Governance (ESG) Scores
Orchestra BioMed's ESG score is a quantitative measure that evaluates Orchestra BioMed's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Orchestra BioMed's operations that may have significant financial implications and affect Orchestra BioMed's stock price as well as guide investors towards more socially responsible investments.
Orchestra Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 211.74 M.Orchestra Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | (0.72) | (0.69) |
Management Efficiency
Orchestra BioMed Holdings has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Orchestra BioMed's management efficiency ratios could be used to measure how well Orchestra BioMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to drop to -0.64. At this time, Orchestra BioMed's Other Current Assets are very stable compared to the past year. As of the 26th of November 2024, Fixed Asset Turnover is likely to grow to 1.87, while Total Assets are likely to drop about 66.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.05 | 2.15 | |
| Tangible Book Value Per Share | 2.05 | 2.15 | |
| Enterprise Value Over EBITDA | (5.36) | (5.63) | |
| Price Book Value Ratio | 4.46 | 4.68 | |
| Enterprise Value Multiple | (5.36) | (5.63) | |
| Price Fair Value | 4.46 | 4.68 | |
| Enterprise Value | 274.5 M | 166.5 M |
The operational strategies employed by Orchestra BioMed management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Operating Margin (16.56) | Beta 0.409 | Return On Assets (0.39) | Return On Equity (0.92) |
Technical Drivers
As of the 26th of November, Orchestra BioMed holds the Risk Adjusted Performance of (0.01), variance of 24.77, and Coefficient Of Variation of (3,626). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orchestra BioMed, as well as the relationship between them.Orchestra BioMed Holdings Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Orchestra BioMed middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Orchestra BioMed Holdings. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Orchestra BioMed Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orchestra BioMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orchestra BioMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Orchestra BioMed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Orchestra BioMed Outstanding Bonds
Orchestra BioMed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Orchestra BioMed Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Orchestra bonds can be classified according to their maturity, which is the date when Orchestra BioMed Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Orchestra BioMed Predictive Daily Indicators
Orchestra BioMed intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Orchestra BioMed stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Orchestra BioMed Corporate Filings
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 23rd of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 26th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 10th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 6th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 15th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 12th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Orchestra BioMed Forecast Models
Orchestra BioMed's time-series forecasting models are one of many Orchestra BioMed's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Orchestra BioMed's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Orchestra Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Orchestra BioMed prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Orchestra shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Orchestra BioMed. By using and applying Orchestra Stock analysis, traders can create a robust methodology for identifying Orchestra entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (17.80) | (16.91) | |
| Operating Profit Margin | (18.66) | (17.73) | |
| Net Loss | (17.80) | (16.91) | |
| Gross Profit Margin | 0.93 | 1.12 |
Current Orchestra Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Orchestra analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Orchestra analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 20.33 | Strong Buy | 5 | Odds |
Most Orchestra analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Orchestra stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Orchestra BioMed Holdings, talking to its executives and customers, or listening to Orchestra conference calls.
Orchestra Stock Analysis Indicators
Orchestra BioMed Holdings stock analysis indicators help investors evaluate how Orchestra BioMed stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Orchestra BioMed shares will generate the highest return on investment. By understating and applying Orchestra BioMed stock analysis, traders can identify Orchestra BioMed position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 19.8 M | |
| Common Stock Shares Outstanding | 33.2 M | |
| Total Stockholder Equity | 68 M | |
| Property Plant And Equipment Net | 2.8 M | |
| Cash And Short Term Investments | 87.6 M | |
| Cash | 30.6 M | |
| Accounts Payable | 2.9 M | |
| Net Debt | -28.9 M | |
| 50 Day M A | 5.4112 | |
| Total Current Liabilities | 11.2 M | |
| Other Operating Expenses | 54.3 M | |
| Non Current Assets Total | 6.1 M | |
| Non Currrent Assets Other | 769 K | |
| Stock Based Compensation | 7.6 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.